[HTML] sciencedirect.com

[HTML][HTML] A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up …

N Banniettis, J Wysocki, L Szenborn, W Phongsamart… - Vaccine, 2022 - Elsevier
Background Despite widespread use of pneumococcal conjugate vaccines (PCVs) in
children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In …
被引用次数：10 相关文章

A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination …

N Banniettis, J Wysocki, L Szenborn, W Phongsamart… - Vaccine, 2022 - cris.bgu.ac.il
Background: Despite widespread use of pneumococcal conjugate vaccines (PCVs) in
children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In …

A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination …

N Banniettis, J Wysocki, L Szenborn, W Phongsamart… - 2022 - cabidigitallibrary.org
Background: Despite widespread use of pneumococcal conjugate vaccines (PCVs) in
children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In …

A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination …

N Banniettis, J Wysocki, L Szenborn… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Despite widespread use of pneumococcal conjugate vaccines (PCVs) in
children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In …

A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination …

V114-024 PNEU-PLAN study group - Vaccine, 2022 - research-repository.uwa.edu.au
Background: Despite widespread use of pneumococcal conjugate vaccines (PCVs) in
children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In …

A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination …

N Banniettis, J Wysocki, L Szenborn, W Phongsamart… - 2022 - trepo.tuni.fi
Background: Despite widespread use of pneumococcal conjugate vaccines (PCVs) in
children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In …

A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination …

N Banniettis, J Wysocki, L Szenborn… - …, 2022 - researchportal.tuni.fi
Background: Despite widespread use of pneumococcal conjugate vaccines (PCVs) in
children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In …

A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination …

V114-024 PNEU-PLAN study group - Vaccine, 2022 - mahidol.elsevierpure.com
Background: Despite widespread use of pneumococcal conjugate vaccines (PCVs) in
children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In …

[引用][C] A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up …

N Banniettis, J Wysocki, L Szenborn, W Phongsamart… - 2022